# A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

> **NCT02519348** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MedImmune LLC** · enrollment: 433 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Tremelimumab
- **BIOLOGICAL:** Durvalumab
- **BIOLOGICAL:** Bevacizumab

## Key facts

- **NCT ID:** NCT02519348
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-10-19
- **Primary completion:** 2020-11-06
- **Final completion:** 2026-04-01
- **Target enrollment:** 433 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02519348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02519348, "A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02519348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*